有静脉血栓栓塞史患者行初次择期全髋关节置换术的多模式预防
研究纳入2004至2018年间257例有静脉血栓栓塞史、接受277例初次择期全髋关节置换术的患者,评估多模式血栓预防在术后120天内的安全性和有效性及第一年死亡率。术后静脉血栓栓塞发生7例(2.5%),死亡7例(2.5%),结论认为多模式预防安全有效。
要点
- 有静脉血栓栓塞史患者行全髋关节置换术后120天内静脉血栓栓塞发生率为2.5%。
- 术后第一年死亡率为2.5%,多数死亡与静脉血栓栓塞或出血无关。
- 作者认为对静脉血栓栓塞史患者多模式预防安全有效,术后抗凝应审慎。
核心结论
- 多模式预防在有静脉血栓栓塞史的患者中是安全有效的。
- 术后抗凝应审慎,因为极少数患者发生静脉血栓栓塞(2.5%)或死于疑似或确诊的肺栓塞。
- 第一年死亡率大多与静脉血栓栓塞或出血无关。
研究设计与样本
- 研究纳入2004至2018年间在单一机构由两位外科医生实施的257例有明确静脉血栓栓塞史患者的277例初次择期全髋关节置换术。
- 患者静脉血栓栓塞史包括深静脉血栓(186例,67%)、肺栓塞(43例,15.5%)或两者兼有(48例,17.5%)。
- 化学预防包括阿司匹林(38例)、抗凝(215例)或阿司匹林联合抗凝(24例)。
- 50例患者(18%)在手术时置有下腔静脉滤器。
- 随访120天记录并发症,随访一年记录死亡率。
主要发现
- 术后诊断静脉血栓栓塞7例(2.5%):深静脉血栓5例,肺栓塞伴深静脉血栓1例,肺栓塞不伴深静脉血栓1例。
- 出院后3例因血肿清除再入院,1例因伤口引流再入院,1例因监测国际标准化比值升高再入院。
- 死亡7例(2.5%);1例术后五个月在开放血栓切除术中死于肺栓塞,该患者已停用抗凝。
- 1例在使用华法林期间死于出血性卒中。
- 其余5例死亡未怀疑肺栓塞或出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We studied the safety and efficacy of multimodal thromboprophylaxis in patients with a history of venous thromboembolism (VTE) who undergo total hip arthroplasty (THA) within the first 120 postoperative days, and the mortality during the first year. Multimodal prophylaxis includes discontinuation of procoagulant medications, VTE risk stratification, regional anaesthesia, an intravenous bolus of unfractionated heparin prior to femoral preparation, rapid mobilization, the use of pneumatic compression devices, and chemoprophylaxis tailored to the patient's risk of VTE. METHODS: Between 2004 to 2018, 257 patients with a proven history of VTE underwent 277 primary elective THA procedures by two surgeons at a single institution. The patients had a history of deep vein thrombosis (DVT) (186, 67%), pulmonary embolism (PE) (43, 15.5%), or both (48, 17.5%). Chemoprophylaxis included aspirin (38 patients), anticoagulation (215 patients), or a combination of aspirin and anticoagulation (24 patients). A total of 50 patients (18%) had a vena cava filter in situ at the time of surgery. Patients were followed for 120 days to record complications, and for one year to record mortality. RESULTS: Postoperative VTE was diagnosed in seven patients (2.5%): DVT in five, and PE with and without DVT in one patient each. After hospitalization, three patients required readmiss-ion for evacuation of a haematoma, one for wound drainage, and one for monitoring of an elevated international normalized ratio (INR). Seven patients died (2.5%). One patient died five months postoperatively of a PE during open thrombectomy. She had discontinued anticoagulation. One patient died of a haemorrhagic stroke while receiving Coumadin. PE or bleeding was not suspected in the remaining five fatalities. CONCLUSION: Multimodal prophylaxis is safe and effective in patients with a history of VTE. Postoperative anticoagulation should be prudent as very few patients developed VTE (2.5%) or died of suspected or confirmed PE. Mortality during the first year was mostly unrelated to either VTE or bleeding. Cite this article: Bone Joint J 2020;102-B(7 Supple B):71-77.
引用
- Gonzalez Della Valle A, Shanaghan KA, Nguyen J, et al. Multimodal prophylaxis in patients with a history of venous thromboembolism undergoing primary elective hip arthroplasty. Bone Joint J. 2020. PMID: 32600195. doi:10.1302/0301-620X.102B7.BJJ-2019-1559.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。